Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus is set to make significant strides in the medical device market as they have shown strong financial performance and have provided bullish financial guidance for the future. Their focus on building their PNS and PRP businesses, along with international expansion and investment in growth drivers, gives the company a solid foundation for growth. With a strong balance sheet, solid cash flow generation, and promising valuation metrics, Bioventus is positioned for success and we recommend considering investment in the company's shares.

Bears say

Bioventus is facing a decline in revenue in their restorative therapies segment, which is primarily due to the recent divestiture of the Advanced Rehab business. The company plans to invest in their ultrasonics business to drive growth through sales expansion and medical education. However, potential growth may be limited as the company expects only low single digit growth in the restorative therapies segment in 2026.

Bioventus (BVS) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 3 analysts, Bioventus (BVS) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.